0000905718-22-000521.txt : 20220331
0000905718-22-000521.hdr.sgml : 20220331
20220331172928
ACCESSION NUMBER: 0000905718-22-000521
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220329
FILED AS OF DATE: 20220331
DATE AS OF CHANGE: 20220331
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sinclair Andrew
CENTRAL INDEX KEY: 0001762451
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36593
FILM NUMBER: 22794595
MAIL ADDRESS:
STREET 1: C/O SOLENO THERAPEUTICS INC.
STREET 2: 1235 RADIO ROAD, SUITE 110
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC
CENTRAL INDEX KEY: 0001484565
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 770523891
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 203 REDWOOD SHORES PARKWAY
STREET 2: SUITE 500
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: 650-213-8444
MAIL ADDRESS:
STREET 1: 203 REDWOOD SHORES PARKWAY
STREET 2: SUITE 500
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
FORMER COMPANY:
FORMER CONFORMED NAME: Capnia, Inc.
DATE OF NAME CHANGE: 20100219
4
1
solenoth_fm4mar292022.xml
X0306
4
2022-03-29
0
0001484565
SOLENO THERAPEUTICS INC
SLNO
0001762451
Sinclair Andrew
203 REDWOOD SHORES PKWY
STE 500
REDWOOD CITY
CA
94065
1
0
0
0
Common Stock
2022-03-29
4
P
0
7720000
A
18022602
I
See Footnotes
Warrant (right to buy)
0.30
2022-03-29
4
P
0
7720000
A
2022-03-29
2027-03-29
Common Stock
7720000
7720000
I
See footnotes
The securities of Soleno Therapeutics, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP.
An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
Each share of common stock was purchased together with one (1) warrant to purchase one (1) share of common stock for an aggregate price of $0.25.
/s/ John Heard, as attorney-in-fact
2022-03-31